Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage.
Addition of increasing amounts of (125)I-labeled desialylated thyroxine-binding globulin (DTBG) to hepatic cell membranes resulted in a progressive increase in binding. Saturability of membrane sites was indicated by a concentration beyond which further increases in [(125)I]DTBG resulted in no further binding. The binding curve for [(125)I]DTBG was similar to binding curves of desialylated orosomucoid, fetuin, and ceruloplasmin. An inhibition assay system using hepatic cell membranes showed that desialylated orosomucoid had a greater affinity for membrane binding sites than did DTBG but desialylated fetuin and ceruloplasmin bound less avidly than DTBG. Serum from normal persons and patients with a variety of illnesses was tested for its ability to inhibit [(125)I]DTBG binding. The inhibitory activity of 1 ml of normal serum was equivalent to that of 0.2-2 mug DTBG. Patients with Laënnec's cirrhosis, biliary cirrhosis, and hepatic metastases had greatly increased inhibitory activity in their serum. Patients with jaundice due to extrahepatic obstruction had inhibitory activity not significantly different from that found in normal serum. Column chromatography of normal serum on Sephadex G-200 resulted in inhibitory activity throughout the range of protein molecular weight. Desialylation of normal serum with neuraminidase enhanced the inhibitory activity but did not change the distribution of the activity. Gel chromatography of cirrhotic serum showed markedly increased inhibitory activity associated with the macroglobulins and the 4.5S peak and a new peak of inhibitory activity in the low molecular weight area was also seen. Inhibition of desialylated glycoprotein binding to liver cell membranes by serum from patients with hepatocellular disease raises the possibility that desialylated serum glycoproteins accumulate in the circulation and that patients with compromised hepatocellular function may no longer be able to clear them from the circulation. Alternatively, accumulation of desialylated glycoproteins in the circulation could result from defective protein synthesis by the diseased liver.
D000510:Alpha-Globulins / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D001797:Blood Protein Electrophoresis; D002462:Cell Membrane / Q000378:metabolism; D002570:Ceruloplasmin / Q000378:metabolism; D002779:Cholestasis / Q000097:blood / Q000378:metabolism; D002850:Chromatography, Gel; D005326:Fetal Proteins / Q000378:metabolism; D006023:Glycoproteins / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000097:blood / Q000378:metabolism; D008107:Liver Diseases / Q000097:blood*; D008113:Liver Neoplasms / Q000097:blood / Q000378:metabolism; D009438:Neuraminic Acids / Q000378:metabolism*; D009961:Orosomucoid / Q000378:metabolism; D011485:Protein Binding; D051381:Rats; D013975:Thyroxine-Binding Proteins / Q000097:blood
D000510:Alpha-Globulins; D005326:Fetal Proteins; D006023:Glycoproteins; D007457:Iodine Radioisotopes; D009438:Neuraminic Acids; D009961:Orosomucoid; D013975:Thyroxine-Binding Proteins; D002570:Ceruloplasmin